Bellevue Group Ag Adaptimmune Therapeutics PLC Transaction History

Bellevue Group Ag

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2019 May 15, 2019	SELL	$3.63 - $6.06 $476,020 - $794,678	-131,135 Closed	0 $0
Q4 2018 Feb 12, 2019	BUY	$3.76 - $14.16 $272,976 - $1.03 Million	72,600 Added 124.03%	131,135 $754,000
Q3 2018 Nov 13, 2018	SELL	$8.27 - $13.56 $11,578 - $18,984	-1,400 Reduced 2.34%	58,535 $794,000
Q2 2018 Aug 07, 2018	BUY	$10.42 - $13.74 $624,522 - $823,506	59,935 New	59,935 $711,000

150M

60.8K

5.8K

Ticker ADAP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 163,370,000
Market Cap $118M
Description
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4...

Get notified when there are updates to the investment portfolio of Bellevue Group Ag, based on Form 13F filings with the SEC.

Stay updated on Bellevue Group Ag with notifications on news.